Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SAT1 | P21673 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045182 | 0.91 | TSHR (0.40) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL10045235 | 0.83 | CYP2C19 (0.59) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL10045234 | 0.83 | CYP2C19 (0.59) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL8062868 | 0.82 | — | — | |
| SCHEMBL9037647 | 0.81 | TSHR (0.50) | TSHRALDH1A1ANPEPERAP2 | |
| SCHEMBL17920167 | 0.79 | ANPEP (0.49) | TSHRALDH1A1ANPEPERAP2 | |
| SCHEMBL13955421 | 0.79 | ANPEP (0.49) | TSHRALDH1A1ANPEPERAP2 | |
| SCHEMBL10045200 | 0.79 | CYP2C19 (0.58) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL10045263 | 0.78 | CYP2C19 (0.65) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL10282736 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2007021839-A2 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHNS HOPKINS UNIVERSITY (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | CYP2C19 4039/4885MEN1 828/4885GLA 941/4885 |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | CYP2C19 4039/4885MEN1 828/4885GLA 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.